![Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fcc11304/MediaObjects/13054_2012_Article_703_Fig2_HTML.jpg)
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
![Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome - ScienceDirect Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2468024923013177-ga1.jpg)
Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome - ScienceDirect
![Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic | Scientific Reports Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-12271-9/MediaObjects/41598_2022_12271_Fig1_HTML.png)
Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic | Scientific Reports
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? | Haematologica
![Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management | Journal of Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management | Journal of](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00415-023-11910-z/MediaObjects/415_2023_11910_Fig3_HTML.png)
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management | Journal of
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/MyHome%20Article%20Library/359740/359740_Thumb_400.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Rituximab therapy in nephrotic syndrome: implications for patients' management | Nature Reviews Nephrology Rituximab therapy in nephrotic syndrome: implications for patients' management | Nature Reviews Nephrology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrneph.2012.289/MediaObjects/41581_2013_Article_BFnrneph2012289_Fig1_HTML.jpg)
Rituximab therapy in nephrotic syndrome: implications for patients' management | Nature Reviews Nephrology
![A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders - Multiple Sclerosis and Related Disorders A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders - Multiple Sclerosis and Related Disorders](https://www.msard-journal.com/cms/asset/67aa659a-acdf-469b-bd42-c7716cfcc977/gr1.jpg)